# Peptides Market

> Peptides Market Research Report: Size, Share, Trend Analysis By Route Of Administration (Oral, Parenteral (Intravenous, Subcutanous, Intramuscular),And Others), By Age Group (Pediatric, And Adult), By Indication (Diabetes Mellitus, Obesity, Short Bowel Syndrome (SBS),Human Growth Hormone (HGH) Deficiency(Pediatrics, Adult) ,Hemophilia, Acromegaly, Hypoparathyroidism ,Cancer, Neurological disorders, Cardiovascular Disorders, Others), By Distribution Channel(Hospital Pharmacies ,Retail Pharmacies, Online Pharmacies) and by Region (North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America ) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.11%
- **2024:** $ 43.12 Billion
- **2025:** $ 46.19 Billion
- **2035:** $ 91.79 Billion
- **Key Players:** Companies such as Novo Nordisk (DK), Bachem AG (CH), PeptiDream Inc. (JP), Thermo Fisher Scientific Inc. (US), Merck KGaA (DE), CordenPharma (DE), Ferring Pharmaceuticals (CH), Hikma Pharmaceuticals (GB), AstraZeneca (GB) are some of the major participants in the Global Peptides Market.

**Report ID:** MRFR/HC/54395-CR · **Pages:** 189 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/peptides-market-56161

---

## Market Summary

## **Global Peptides Market Overview**

Peptides Market Size Was Valued at USD 43.12 Billion In 2024. The Global Peptides Industry is Projected to Grow from USD 45.58 Billion In 2025 To USD 97.18 Billion By 2035, Exhibiting A Compound Annual Growth Rate (CAGR) Of 7.11% During the Forecast Period (2025 - 2035).

Growing Awareness of Peptide-Based Therapeutics and Growing Acquisition and Agreement Associated With The Peptide Products And Increasing Launch of Platform To Accelerate Peptide Drug Discovery Research is driving the Peptides Market.

As per Analyst at MRFR,” The growing awareness of peptide-based therapeutics is significantly boosting the global market for peptide drugs, as more healthcare professionals and patients recognize their potential in treating a variety of conditions, including cancer, diabetes, and autoimmune disorders. As peptides are increasingly understood for their specificity and reduced side effects compared to traditional small molecule drugs, demand for these innovative therapies is surging”

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

## **Peptides Market Trends**

### **Increasing Funding Associated With Peptide Platform And Drug**

Increasing funding and investment in the global peptide market is poised to unlock significant lucrative opportunities by accelerating research and development, enhancing production capabilities, and expanding market reach. With more financial resources, companies can innovate in peptide synthesis and formulation, leading to the development of novel therapeutic applications in areas such as oncology, diabetes, and autoimmune diseases.

This influx of capital can also facilitate partnerships and collaborations, driving advancements in technology and improving manufacturing processes for greater efficiency and scalability. For instance,

#### **March 2024: Grant for Prostate Cancer Therapy**

Department of Urology at The University of Kansas Cancer Center has received a nearly USD 1.4 billion grant from the U.S. Department of Defense (DoD) to develop a short peptide-based therapy for prostate cancer. As prostate cancer progresses, it often develops resistance to standard treatments like androgen-deprivation therapy and androgen receptor antagonists.

This resistance presents significant challenges in effective treatment. However, recent research indicates a potential breakthrough by targeting the stability of the androgen receptor protein, a critical factor in the cancer's development and progression. The grant will support further exploration of this innovative therapeutic approach.

#### **July 2024: CordenPharma Investment in Peptide Plants**

CordenPharma (US) had made a substantial investment of nearly one billion dollars in peptide plants across the US and Europe, driven by the surging popularity of peptide-based weight-loss and antidiabetes drugs. The strong demand for glucagon-like peptide 1 (GLP-1) agonists is a primary catalyst for CordenPharma to expand its peptide services.

Additionally, the growing need for peptides in areas such as oncology and radiopharmaceuticals further underscore this investment. With part of the new funding, CordenPharma plans to add reactors for peptide synthesis at its Boulder, Colorado facility, enhancing its production capabilities.

The company is also set to establish a new facility in Europe dedicated to early-to-late-stage commercial manufacturing, positioning itself to meet the increasing global demand for peptide therapies.

## **Peptides Market Segment Insights**

### **Global Peptides Route of Administration Insights**

Based on Route of Administration, the Peptides Market has been bifurcated into Oral and Parenteral. Parenteral is further segmented into Intravenous, Subcutaneous, and Intramuscular. The parenteral segment held the largest market share in 2024, and the oral segment is the fastest-growing segment during the forecast period (2024 -2035).

The oral route has gained traction due to its non-invasive nature, making it more convenient for patients, particularly for chronic diseases requiring long-term therapy. According to the Centre for Diseases Control and Prevention in 2019, the prevalence of chronic diseases in adults was around 60% globally, and it is reportedly much higher among elderly people. It is estimated that about 70% of adults will die of one or more chronic diseases. The rising prevalence of cancer, cardiovascular disorders, diabetes, Parkinson's disease, and other conditions demands oral medications.

However, challenges such as the low bioavailability of peptides via the oral route have driven significant research into advanced formulations to improve peptide absorption. Government agencies, particularly in the US and Europe, have supported initiatives that encourage innovation in oral peptide formulations, aiming to enhance patient compliance and reduce healthcare costs. The rising focus on patient-friendly drug delivery systems and growing interest in self-administrable therapies are key drivers in this segment.

On the other hand, the parenteral route dominates the peptides market due to its higher efficacy and bioavailability. Intravenous administration is more favored for critical care treatments such as cardiovascular diseases and others requiring quick onset action. Government healthcare expenditure for critical care treatments in developed markets such as the US, Japan, and Europe for a disease like cancer has helped increase the adoption rate of IV peptide treatments.

Subcutaneous administration is highly used for chronic conditions such as diabetes and obesity with various long-acting peptide formulations that have obtained market approval. For instance, in June 2021, semaglutide (2.4 mg, Wegovy) received USFDA approval as a treatment for obesity or overweight in adults. Apart from this, the rise in chronic diseases, improvement in healthcare infrastructure in emerging markets like China and India, is thus supporting growth in the Subcutaneous segment.

Besides, Intramuscular peptide administration is showing steady growth, more so in hormonal treatments such as human growth hormone deficiency and hypoparathyroidism where sustained-release formulations are developed.

### **Global Peptides Age Group Insights**

Based on Age Group, the Peptides Market has been bifurcated into Pediatrics and Adult. The adult segment held the largest market in 2024, and the pediatric segment is the fastest growing segment during the forecast period.

In the Pediatrics segment, the incidence of pediatric diseases has been on the rise with diseases such as diabetes, growth hormone deficiencies, and rare genetic disorders. Ensuring better outcomes for the future generation around the globe has become a goal and priority among governments and healthcare organizations when it comes to advanced treatments like peptide therapy.

Pediatric preparations of peptide drugs are designed to be sensitive to the diverse metabolic and physiological needs of children and thereby increase the scope for clinical trials and investments in R&D. The incidence of pediatric diabetes is on the rise not only in developing nations but also in well-developed nations like the US and Europe, due to which there is an increased effort in developing child-friendly peptide-based treatments for glycemic control. According to global health statistics, the incidence of pediatric endocrine disorders has been gradually increasing over the last decade. This further increases the demand for innovative therapies.

The dominant chronic diseases like cardiovascular diseases and metabolic disorders with a growing prevalence have constituted an important growth driver in the Adult segment of peptide-based treatments. Peptide therapies are also increasingly trending in adults. This can be seen in the management of age-related conditions such as neurodegenerative diseases.

Moreover, the sales of peptides for anti-obesity and anti-diabetic treatments will grow with the increasing rates of obesity and diabetes in developed and developing countries. In this regard, the public, government, and health administrations have made investments in the development of medical products and been placing peptide medicine on the commercial map. Indeed, in 2020, FDA and EMA approvals for peptide drugs treating adults showed significant surge.

Figure 1: Peptides Market, By Age Group, 2024 & 2035 (USD Billion)

### **Global Peptides Indication Insights**

Based on Indication, the Peptides Market has been segmented into Diabetes Mellitus, Obesity, Short Bowel Syndrome (SBS), Human Growth Hormone (hGH) Deficiency, Hemophilia, Acromegaly, Hypoparathyroidism, Cancer, Neurological disorders, Cardiovascular Disorders, and Others. Human Growth Hormone (hGH) Deficiency is further bifurcated into Pediatrics and Adult. The diabetes mellitus segment held the largest market in 2024, and the human growth hormone (HGH) segment is the fastest growing segment during the forecast period.

Diabetes Mellitus is one of the primary drivers for the peptide market due to the rising global incidence of diabetes. According to the International Diabetes Federation (IDF), in 2021, approximately 537 billion people worldwide were living with diabetes, and this number is expected to soar to 643 billion by 2030. Similarly, according to the American Diabetes Association, diabetes affected 38.4 billion Americans, or 11.6% of the population, in 2021. Type 1 diabetes affects around 2.0 billion Americans, including approximately 304,000 children and adolescents.

The growing adoption of peptide-based therapies, particularly GLP-1 receptor agonists such as Liraglutide and Semaglutide, is playing a critical role in improving glycemic control and reducing the risk of cardiovascular complications in diabetic patients. Governments in regions like the US, Europe, and Asia-Pacific are increasing healthcare expenditure to manage the diabetes burden, thereby promoting the use of innovative peptide therapies.

Similarly, the growing prevalence of obesity is another key factor driving the demand for peptides. According to the WHO, in 2022, one in eight individuals globally was living with obesity. Peptide-based treatments like GLP-1 analogs are gaining popularity as they aid in appetite suppression and weight loss. The increased government focus on tackling obesity-related diseases, combined with rising public health initiatives, is boosting the growth of this segment.

In the case of Short Bowel Syndrome (SBS), the increasing number of cases, especially in pediatric populations, is driving demand for peptide-based therapies that improve nutrient absorption. Teduglutide, a peptide therapy approved by the FDA, has become a major therapeutic option for SBS patients, addressing the malabsorption issues inherent to the condition. This, along with government support for orphan drugs and rare disease treatments, is expected to accelerate the adoption of peptide therapies for SBS.

### **Global Peptides Distribution Channel Insights**

Based on Distribution Channel, the Peptides Market has been segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment held the largest market in 2024, and the online pharmacies segment is the fastest growing segment during the forecast period.

Due to increased prescription of peptide-based drugs in critical and complex conditions such as diabetes, and cardiovascular diseases among others, drug therapy in hospitals forms a vast market. Hospitals are centers that have the sole responsibility of carrying out peptide therapy, especially for critical care and specialized treatments. The world is witnessing an in-crease in hospital admissions with chronic diseases. With the availability of advanced peptide drugs on the hospitals, this segment is experiencing a boost in demand.

The hospitals are not only working on the infrastructure of hospitals but are also upgrading the therapeutics available to patients, which include access to peptides, further fueling the market.

Retail Pharmacies are also seeing a steady hike in the demand for peptide drugs. With more peptide-based drugs receiving approval for outpatient use, the treated patients can directly buy these drugs from retail pharmacies. Increasingly diagnosed lifestyle diseases like obesity and diabetes in the body have increased the demand for peptide therapies, many of which are now available in retail pharmacies. The convenience of accessing peptide-based drugs through a retail outlet, along with an enhancement of the pharmaceutical chain, is also a key growth driver for this segment.

Public health initiatives and insurance coverage for drugs taken for chronic diseases have cemented the retail pharmacies in the marketplace of peptides.

Online pharmacies are fast growing as well in this era of e-health. Online patients, desiring accessibility and convenience, especially while taking chronic diseases, are opting for buying peptide drugs on online platforms. Telemedicine, digital health platforms, and online prescription services have made the process of acquiring peptide medications much easier through personal homes. Governments in regions such as North America and Europe encourage the digitization of healthcare services, which boosts the consumption of online pharmacies. Acceptance of online pharmacies, competitive pricing, and home delivery options are factors driving this segment's growth

## **Global Peptides Regional Insights**

Based on region, the Global Peptide Market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share in 2024 and is anticipated to reach USD 31.58 billion by 2035. However, Asia-Pacific is projected to grow at the highest CAGR of 8.42% during the forecast period.

### **North America Peptide Market**

The North America Peptide Market accounted for largest market share during the forecast period. North America is further segmented into the US, & Canada. The peptides market in North America is thriving, characterized by a dynamic interplay of innovation and demand. This growth is primarily fueled by the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, which drives the need for effective peptide-based therapeutics.

According to the US Department of Health and Human Services, around 129 billion people in the US have at least one significant chronic disease (for example, heart disease, cancer, diabetes, obesity, or hypertension). Five of the top ten main causes of death in the United States are either preventable or closely connected with chronic conditions that can be treated. Over the last two decades, prevalence has steadily climbed, and this pattern is projected to continue. An increasing proportion of Americans suffer from several chronic illnesses; 42% have two or more, and 12% have at least five.

Aside from the personal effects, chronic sickness has a significant influence on the US healthcare system. Approximately 90% of the $4.1 trillion spent on health care each year goes toward managing and treating mental health issues and chronic illnesses. On the other hand, according to Statistique Canada, in 2021, 45.1% of Canadians had at least one serious chronic illness. In 2021, around 2.5 billion Canadians reported having unmet medical needs.

### **Asia-Pacific Peptide Market**

The Asia-Pacific Peptide is projected to grow at a CAGR of 8.42% during the forecast period. Asia-Pacific is further segmented into the China, India, Japan, South Korea, Australia, and Rest of Asia-pacific.

The peptide market in the Asia-Pacific region is undergoing remarkable growth, fueled by a multifaceted array of drivers that are shaping its landscape. One of the most significant factors is the rising incidence of chronic diseases, including diabetes, cancer, and cardiovascular conditions. For instance, According to National Institute of Health, over 60% of diabetics living in Asia, with China and India accounting for nearly half of the total. More than 138.2 billion people in the Western Pacific, the most populated region in the globe, have diabetes, and by 2035, that figure might reach 201.8 billion.

As these health challenges become more prevalent, the demand for effective peptide-based therapeutics is surging, prompting healthcare providers to seek innovative treatment options.

Figure 2: Peptides Market, by region, 2024 & 2035 (USD Billion)

Further, the major countries studied in the market report are the U.S., Canada, Mexico, Germany, France, Italy, UK, Spain, Japan, UAE, South Africa, Saudi Arabia, Argentina, and Brazil.

## **Global Peptides Key Market Players & Competitive Insight**

Many global, regional, and local vendors characterize the Peptides Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.

The major players in the market include AMGEN INC., ELI LILLY AND COMPANY, PFIZER INC., SUN PHARMACEUTICAL INDUSTRIES LTD., MERCK KGAA, TAKEDA PHARMACEUTICAL COMPANY LIMITED, ASTRAZENECA, NOVARTIS AG, SANOFI, IRONWOOD PHARMACEUTICALS, INC., among others. The Peptides Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

### **Key Companies in the Peptides Market include:**

- AMGEN INC.
- ELI LILLY AND COMPANY
- PFIZER INC.
- SUN PHARMACEUTICAL INDUSTRIES LTD.
- MERCK KGAA
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- ASTRAZENECA
- [NOVARTIS AG](https://www.novartis.com/about/products)
- SANOFI
- IRONWOOD PHARMACEUTICALS, INC.

## **Global Peptides Industry Developments**

### **August 2024: Eli Lilly and Company - Zepbound (tirzepatide) Availability**

In August 2024, Eli Lilly and Company has announced that Zepbound (tirzepatide) is now available for self-pay patients with an on-label prescription, greatly increasing the supply in response to high demand. The single-dose vials are offered at a discount of 50% or more compared to the list prices of other GLP-1 medications for obesity. The single-dose vials are priced at a discount of 50% or more compared to the list prices of all other GLP-1 medications for obesity.

### **January 2024: Takeda and Protagonist Therapeutics, Inc. - Rusfertide Agreement**

In January 2024, Takeda and Protagonist Therapeutics, Inc. have signed a global license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin that was in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera (PV).

## **Peptides Market Segmentation**

### **Peptides Market By Route Of Administration Outlook (USD Billion, 2019-2035)**

- Oral
- Parenteral - [Intravenous](../../../reports/intravenous-equipment-market-32694) - Subcutaneous - Intramuscular
- Others

### **Peptides Market By Age Group Outlook (USD Billion, 2019-2035)**

- Pediatrics
- Adult

### **Peptides Market By Indication Outlook (USD Billion, 2019-2035)**

- Diabetes Mellitus
- Obesity
- Short Bowel Syndrome (SBS)
- Human Growth Hormone (HGH) Deficiency - Pediatrics - Adult
- Hemophilia
- Acromegaly
- Hypoparathyroidism
- Cancer
- Neurological disorders
- Cardiovascular Disorders
- Others

### **Peptides Market By Distribution Channel Outlook (USD Billion, 2019-2035)**

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

## **Global Peptides Regional Outlook**

- North America - US - Canada - Mexico
- Europe - Germany - France - UK - Spain - Italy - Rest of Europe
- Asia-Pacific - China - Japan - India - South Korea - Rest of Asia-Pacific
- Middle East and Africa
- Latin America

## Market Drivers

### Rising Prevalence of Chronic Diseases

The Peptides Market is significantly influenced by the rising prevalence of chronic diseases, including diabetes, cancer, and cardiovascular disorders. As these health issues become more widespread, there is an increasing demand for effective therapeutic solutions. Peptides have emerged as promising candidates for the treatment of various chronic conditions due to their specificity and lower side effects compared to traditional drugs.
 
Market data suggests that the peptide therapeutics segment is expected to grow at a rate of around 8% annually, reflecting the urgent need for innovative treatments. This trend underscores the importance of the Peptides Market in addressing global health challenges and highlights the potential for new peptide-based therapies to enter the market.

### Expansion of Research in Immunotherapy

The Peptides Market is benefiting from the expansion of research in immunotherapy, a field that is gaining traction in the treatment of various diseases, including cancer. Peptides are increasingly recognized for their potential to enhance immune responses and target specific antigens, making them valuable tools in immunotherapeutic strategies.
 
Recent studies have shown that peptide-based vaccines can elicit robust immune responses, leading to promising clinical outcomes. The immunotherapy market is expected to grow significantly, with projections indicating a value exceeding 100 billion by 2025. This growth is likely to drive further investment and research in peptide applications, positioning the Peptides Market as a key player in the evolving landscape of cancer treatment and beyond.

### Increasing Investment in Biotechnology

The Peptides Market is experiencing a surge in investment, particularly in biotechnology sectors. This trend is driven by the growing recognition of peptides as vital components in [drug development](https://www.marketresearchfuture.com/reports/drug-development-market-66529) and therapeutic applications. In recent years, funding for peptide research has escalated, with estimates indicating that the biotechnology sector could reach a valuation of over 800 billion by 2025.
 
This influx of capital is likely to enhance research capabilities, leading to innovative peptide-based therapies. Furthermore, collaborations between academic institutions and pharmaceutical companies are becoming more prevalent, fostering an environment conducive to breakthroughs in peptide applications. As a result, the Peptides Market is poised for substantial growth, with new products and therapies emerging from this collaborative research landscape.

### Growing Interest in Anti-Aging Products

The Peptides Market is witnessing a notable increase in demand for anti-aging products, particularly in the cosmetics sector. Consumers are becoming more aware of the benefits of peptides in skincare formulations, which are known to promote collagen production and improve skin elasticity.
 
Market Research Future indicates that the global anti-aging market is projected to reach over 300 billion by 2025, with peptides playing a pivotal role in this growth. This trend is further fueled by the rising aging population, which is driving the need for effective skincare solutions. As a result, the Peptides Market is likely to see a proliferation of peptide-infused cosmetic products, catering to the evolving preferences of consumers seeking youthful and radiant skin.

### Advancements in Peptide Synthesis Technologies

Technological advancements in peptide synthesis are playing a crucial role in the Peptides Market. Innovations such as solid-phase peptide synthesis and automated synthesizers have significantly improved the efficiency and scalability of peptide production. These advancements enable the synthesis of complex peptides that were previously challenging to produce, thereby expanding the range of potential applications.
 
The market for peptide synthesis technologies is projected to grow at a compound annual growth rate of approximately 10% over the next few years. This growth is indicative of the increasing demand for high-quality peptides in pharmaceuticals and research. Consequently, the Peptides Market is likely to benefit from these technological improvements, leading to enhanced product offerings and increased market penetration.

## Future Outlook

The Peptides Market size is projected to reach USD 91.79 Billion by 2035, growing at a CAGR of 7.11%.

**New opportunities:**

- Development of targeted [peptide therapeutics](https://www.marketresearchfuture.com/reports/peptide-therapeutics-market-22758) for chronic diseases. Expansion of peptide-based diagnostics in personalized medicine. Investment in automated peptide synthesis technologies for cost efficiency.

By 2035, the Peptides Market is expected to achieve substantial growth, driven by innovation and strategic investments.

## Segment Insights

### By Route Of Administration: Parenteral (Largest) vs. Subcutaneous (Fastest-Growing)

The Peptides Market is significantly influenced by the route of administration, with the parenteral route holding the largest market share. Parenteral administration includes various forms like intravenous and intramuscular, appealing widely due to their effectiveness and quick action. In contrast, the subcutaneous route, while smaller in market share, is emerging rapidly as a preferred method for certain peptides due to its ease of use and patient convenience.

Administration: Parenteral (Dominant) vs. Subcutaneous (Emerging)

Parenteral administration is characterized by its direct introduction of peptides into the bloodstream, ensuring rapid absorption and high bioavailability. This route remains dominant within the Peptides Market, especially for therapeutic peptides that require immediate effect. On the other hand, the subcutaneous route is increasingly being recognized for its emerging popularity, particularly for self-administration and chronic therapy setups. It offers practical advantages, such as ease of use and reduced frequency of administration, making it an attractive option for patients and healthcare providers alike. As advancements in formulation technology continue, the subcutaneous route is expected to gain further traction.

### By Age Group: Pediatrics (Largest) vs. Adult (Fastest-Growing)

The Peptides Market exhibits a diverse distribution among its age group segments, with Pediatrics holding the largest share. This dominance can be attributed to the increasing focus on pediatric care and the growing prevalence of conditions necessitating peptide therapies in younger populations. Conversely, the Adult segment, while currently smaller, showcases significant growth potential due to rising health concerns and an increasing incidence of chronic diseases among adults, especially in the aging population. The growth trends in the Peptides Market predominantly favor the Adult segment, which is experiencing rapid expansion driven by advancements in peptide-based therapeutics and personalized medicine. Increasing investments in research and development specific to adult-targeted peptide therapies highlight the segment's growth dynamics. Additionally, the surge in healthcare awareness regarding preventive measures, chronic disease management, and innovative treatment options is catalyzing the emergence of the Adult segment as a key player in the market landscape.

Pediatrics: Dominant vs. Adult: Emerging

In the Peptides Market, the Pediatrics segment is characterized by its strong presence and established demand for peptide therapies addressing developmental and chronic health conditions in younger patients. This segment is recognized for its extensive range of peptide treatments, including those for hormonal deficiencies and growth disorders. Pediatricians increasingly incorporate peptide therapies into treatment plans, supporting its dominant market position. On the other hand, the Adult segment is emerging rapidly, driven by broader awareness of adult health issues and significant clinical advancements. It includes therapies targeting aging populations and chronic conditions such as diabetes and cardiovascular diseases. The Adult market is evolving with innovative peptide products and personalized approaches, creating opportunities for growth and attracting investments into research focused on adult care.

### By Indication: Diabetes Mellitus (Largest) vs. Obesity (Fastest-Growing)

In the Peptides Market, the indication segment reveals significant diversity in terms of market share, with Diabetes Mellitus standing out as the largest segment due to the rising prevalence of diabetes and increasing demand for effective treatment options. Following closely is Obesity, which is rapidly gaining traction, driven by the rising global obesity rates and increasing awareness about related health risks. Other segments, such as Short Bowel Syndrome and Human [Growth Hormone deficiency](https://www.marketresearchfuture.com/reports/growth-hormone-deficiency-market-10430), maintain smaller yet notable shares, illustrating the vast range of peptide applications.

Diabetes Mellitus (Dominant) vs. Obesity (Emerging)

Diabetes Mellitus represents the dominant segment within the Peptides Market, characterized by a well-established range of peptide-based therapies that effectively manage blood sugar levels and improve patient outcomes. The growth in this segment is supported by advancements in research and development, leading to innovative treatment options. In contrast, Obesity is seen as an emerging segment, with novel peptide therapeutics aimed at weight management experiencing rapid growth. This segment appeals due to increasing health concerns associated with obesity, and as awareness rises, the demand for effective peptide solutions continues to expand. Both segments display distinct characteristics, with Diabetes Mellitus showing stability and a well-defined market, while Obesity showcases high growth potential as new treatments are developed.

### By Distribution Channel: Hospital Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing)

In the Peptides Market, the distribution of market share among various channels reveals that Hospital Pharmacies occupy the largest segment, due to their established infrastructure and strong relationships with healthcare providers. Retail Pharmacies also hold a significant portion of the market, facilitating access to peptides for a wider population, though their share is gradually being challenged by the rise of online alternatives. Online Pharmacies are gaining traction as they offer convenience and accessibility, appealing particularly to tech-savvy consumers.

Retail Pharmacies (Dominant) vs. Online Pharmacies (Emerging)

Retail Pharmacies play a dominant role in the Peptides Market as they provide immediate access to essential medications and treatments related to peptides. Their established networks and customer loyalty contribute to their strong market position. In contrast, Online Pharmacies are emerging rapidly, driven by changing consumer preferences for convenience and the ability to order medications discreetly. This shift is powered by advancements in technology and logistics, allowing online platforms to offer competitive pricing and wider selections. As both segments evolve, the competition between retail and online pharmacies will likely intensify, shaping future market dynamics.

## Regional Market Share Analysis

### North America : Innovation and Market Leadership

North America is the largest market for peptides, holding approximately 45% of the global share, driven by advanced research facilities, high healthcare expenditure, and a robust pharmaceutical sector. The region benefits from strong regulatory support, particularly from the FDA, which facilitates the approval of peptide-based therapeutics. The increasing prevalence of chronic diseases and the growing demand for personalized medicine further fuel market growth.

The United States leads the North American market, with significant contributions from Canada. Key players such as Thermo Fisher Scientific Inc. and Novo Nordisk are at the forefront, driving innovation and expanding their product portfolios. The competitive landscape is characterized by strategic partnerships and collaborations among leading firms, enhancing their market presence and technological capabilities.

### Europe : Regulatory Support and Growth

Europe is the second-largest market for peptides, accounting for approximately 30% of the global share. The region's growth is propelled by increasing investments in biotechnology and pharmaceutical research, alongside supportive regulatory frameworks from the European Medicines Agency (EMA). The rising incidence of metabolic disorders and the demand for targeted therapies are key drivers of market expansion, with countries like Germany and the UK leading the charge.

Germany, the UK, and Switzerland are the primary contributors to the European peptide market, hosting several key players such as Merck KGaA and Bachem AG. The competitive landscape is marked by a focus on innovation, with companies investing heavily in R&D to develop novel peptide therapeutics. Collaborations between academia and industry are also fostering advancements in peptide technology, enhancing the region's position in the global market.

### Asia-Pacific : Rapid Growth and Investment

The Asia-Pacific region is witnessing rapid growth in the peptides market, holding approximately 20% of the global share. This growth is driven by increasing healthcare investments, a rising population, and a growing focus on biotechnology. Countries like China and Japan are at the forefront, with supportive government initiatives aimed at enhancing research and development in peptide therapeutics. The region's expanding healthcare infrastructure is also a significant catalyst for market growth.

China is emerging as a key player in the peptide market, with substantial investments in biotechnology and pharmaceutical sectors. Japan follows closely, with established companies like PeptiDream Inc. leading the innovation curve. The competitive landscape is characterized by a mix of local and international players, with a focus on developing cost-effective peptide solutions to meet the growing demand for advanced therapeutics.

### Middle East and Africa : Untapped Potential and Growth

The Middle East and Africa (MEA) region is gradually emerging in the peptides market, currently holding about 5% of the global share. The growth is primarily driven by increasing healthcare expenditure, rising awareness of peptide-based therapies, and a growing focus on biotechnology. Countries like South Africa and the UAE are leading the market, supported by government initiatives aimed at enhancing healthcare infrastructure and research capabilities.

South Africa is the largest market in the MEA region, with a growing number of local and international players entering the market. The competitive landscape is evolving, with companies focusing on developing innovative peptide solutions to cater to the increasing demand for advanced therapeutics. Collaborations between governments and private sectors are also fostering growth, paving the way for a more robust peptide market in the region.

## Competitive Benchmarking

The Peptides Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for therapeutic peptides and advancements in biotechnology. Key players are actively engaging in strategies that emphasize innovation, regional expansion, and strategic partnerships. Companies such as Novo Nordisk (Denmark), Bachem AG (Switzerland), and PeptiDream Inc. (Japan) are at the forefront, leveraging their expertise to enhance their market positions. Novo Nordisk (Denmark) focuses on diabetes and obesity treatments, while Bachem AG (Switzerland) emphasizes the production of high-quality peptides for pharmaceutical applications. PeptiDream Inc. (Japan) is known for its proprietary peptide discovery platform, which allows for the rapid development of novel therapeutics, thereby shaping the competitive environment through technological advancements.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The Peptides Market appears to be moderately fragmented, with a mix of established players and emerging companies. The collective influence of these key players is significant, as they not only drive innovation but also set industry standards that smaller firms often follow.

In August 2025, Novo Nordisk (Denmark) announced a strategic partnership with a leading biotechnology firm to co-develop a new class of peptide-based therapies aimed at treating metabolic disorders. This collaboration is expected to enhance Novo Nordisk's research capabilities and accelerate the development of innovative treatments, thereby reinforcing its position in the market. The strategic importance of this partnership lies in its potential to expand the company's product pipeline and address unmet medical needs in the metabolic disorder space.

In September 2025, Bachem AG (Switzerland) unveiled a new state-of-the-art manufacturing facility in the United States, aimed at increasing production capacity for its peptide synthesis. This expansion is crucial as it allows Bachem to meet the growing demand for high-quality peptides in North America, thereby strengthening its market presence. The establishment of this facility not only enhances operational efficiency but also positions Bachem as a key player in the North American peptide market.

In July 2025, PeptiDream Inc. (Japan) entered into a collaboration with a major pharmaceutical company to develop peptide-based therapeutics for oncology applications. This strategic move is indicative of PeptiDream's commitment to expanding its therapeutic focus and leveraging its innovative platform. The collaboration is likely to enhance the company's visibility in the oncology sector, which is experiencing rapid growth and presents significant opportunities for peptide-based treatments.

As of October 2025, the Peptides Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of agility and adaptability in a rapidly changing market.

## Recent News & Developments

### **August 2024: Eli Lilly and Company - Zepbound (tirzepatide) Availability**

In August 2024, Eli Lilly and Company has announced that Zepbound (tirzepatide) is now available for self-pay patients with an on-label prescription, greatly increasing the supply in response to high demand. The single-dose vials are offered at a discount of 50% or more compared to the list prices of other GLP-1 medications for obesity. The single-dose vials are priced at a discount of 50% or more compared to the list prices of all other GLP-1 medications for obesity.

### **January 2024: Takeda and Protagonist Therapeutics, Inc. - Rusfertide Agreement**

In January 2024, Takeda and Protagonist Therapeutics, Inc. have signed a global license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin that was in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera (PV).

## Report Scope

| MARKET SIZE 2024 | 43.12(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 46.19(USD Billion) |
| MARKET SIZE 2035 | 91.79(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.11% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Novo Nordisk (DK), Bachem AG (CH), PeptiDream Inc. (JP), Thermo Fisher Scientific Inc. (US), Merck KGaA (DE), CordenPharma (DE), Ferring Pharmaceuticals (CH), Hikma Pharmaceuticals (GB), AstraZeneca (GB) |
| Segments Covered | Route Of Administration, Age Group, Indication, Distribution Channel, Region |
| Key Market Opportunities | Growing demand for personalized medicine drives innovation in the Peptides Market. |
| Key Market Dynamics | Rising demand for therapeutic peptides drives innovation and competition among pharmaceutical companies in the peptides market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Peptides Market as of 2024?**
A: The Peptides Market was valued at 43.12 USD Billion in 2024.

**Q: What is the projected market size for the Peptides Market by 2035?**
A: The Peptides Market is projected to reach 91.79 USD Billion by 2035.

**Q: What is the expected CAGR for the Peptides Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Peptides Market during the forecast period 2025 - 2035 is 7.11%.

**Q: Which route of administration segment shows the highest projected growth?**
A: The parenteral route of administration segment is projected to grow from 15.0 to 30.0 USD Billion by 2035.

**Q: How does the market for peptides in pediatrics compare to adults?**
A: The market for peptides in pediatrics is expected to grow from 8.62 to 18.25 USD Billion, while the adult segment is projected to increase from 34.5 to 73.54 USD Billion.

**Q: What are the leading indications driving the Peptides Market?**
A: Key indications include diabetes mellitus, projected to grow from 8.0 to 17.0 USD Billion, and cancer, expected to rise from 7.0 to 15.0 USD Billion.

**Q: Which distribution channel is anticipated to dominate the Peptides Market?**
A: Online pharmacies are expected to dominate, with growth projected from 18.12 to 41.79 USD Billion by 2035.

**Q: Who are the key players in the Peptides Market?**
A: Key players include Novo Nordisk, Bachem AG, and Thermo Fisher Scientific, among others.

**Q: What is the projected growth for the intravenous administration segment?**
A: The intravenous administration segment is projected to grow from 10.0 to 20.0 USD Billion by 2035.

**Q: How does the market for peptides address neurological disorders?**
A: The market for peptides addressing neurological disorders is expected to grow from 5.0 to 10.0 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/peptides-market-56161*